Immunome Inc Dossier
Qualitative Analysis
Business overview
Immunome Inc. (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company dedicated to developing first-in-class and best-in-class targeted cancer therapies, with a primary focus on antibody-drug conjugates (ADCs) and other innovative oncology modalities. The company's proprietary discovery engine leverages human memory B cells to identify novel antibodies and targets. Its clinical pipeline is anchored by varegacestat, an investigational oral gamma-secretase inhibitor that recently met its primary endpoint in the Phase 3 RINGSIDE trial for desmoid tumors. Additionally, Immunome is rapidly expanding its ADC portfolio, which includes clinical-stage assets like IM-1021 (a ROR1-targeted ADC) and IM-1617, alongside preclinical programs such as IM-3050 (a FAP-targeted radioligand therapy).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on the regulatory, manufacturing, and commercial readiness activities necessary to position varegacestat (formerly AL102) for FDA approval and subsequent commercial launch in desmoid tumors.
Expected impact: Establishes the company's first commercial product and generates recurring product revenue.
Advancing a proprietary pipeline of solid tumor-targeted ADCs incorporating the HC74 TOP1 inhibitor payload, including clinical-stage IM-1021 and newly clinical IM-1617, alongside planned IND submissions for IM-1340 and IM-1335.
Expected impact: Diversifies the pipeline beyond a single late-stage asset and establishes a robust multi-asset oncology franchise.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired the late-stage investigational oral gamma-secretase inhibitor varegacestat (AL102) and AL101, shifting Immunome's identity toward precision oncology with a near-term registrational asset.
Financial impact: Upfront consideration of $20 million in cash and 2,175,489 shares of common stock (valued at $30 million), with up to $37.5 million in contingent development and commercial milestones.
Merged to establish a preeminent oncology company, adding targeted oncology platform capabilities, a folate receptor-targeted TLR7 agonist, and a FAP-targeted radioligand (IM-3050), while appointing Dr. Clay Siegall as CEO.
Financial impact: All-stock transaction valued at approximately $51.7 million, accompanied by a concurrent $125 million private placement (PIPE) investment.
Strategic Partnerships
Grants Immunome an exclusive, worldwide license to monoclonal antibodies directed against a single undisclosed target to expand its ADC pipeline.
Terms: Hummingbird Bioscience received an upfront payment and is eligible for future development and commercial milestone payments, as well as royalties.
Secured exclusive worldwide rights to a panel of monoclonal antibodies targeting an undisclosed target, allowing Immunome to pair them with its proprietary linker-payload technologies.
Terms: Nectin received an upfront payment and is eligible for future milestone payments and royalties.